<DOC>
	<DOCNO>NCT00254748</DOCNO>
	<brief_summary>In patient schizophrenia , 'atypical ' antipsychotic clozapine may effective treatment psychosis . In patient borderline personality disorder ( BPD ) , far investigator know , well design control study perform effect one new atypical antipsychotic psychotic symptom . It interest investigate benefit quetiapine treatment type patient . Quetiapine possibly give less side-effects expect lack elevated prolactin level , importance patient group , overrepresented young female . In double blind , randomize , placebo control , 8 week , parallel group , multi-center study , quetiapine ( flexible dose 200 mg/day 600 mg/day ) compare placebo .</brief_summary>
	<brief_title>Verkes Borderline Study : The Effect Quetiapine Borderline Personality Disordered Patients</brief_title>
	<detailed_description />
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients BPD accord Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) /Structured Clinical Interview DSMIV Axis II Personality Disorders ( SCIDII ) include criterion 9 : transient , stress relate paranoid ideation severe dissociative symptom . In outpatient Depressive disorder Bipolar disorder Schizoaffective disorder/schizophrenia/delusional disorder/schizotypal personality disorder Alcohol substance dependence Quetiapine dose &gt; 100mg od use past Somatic : History trauma capitis Visual auditive disorder Neurological disorder ( epilepsy ) Pregnancy No adequate contraception History cardial complaints/cardiological disorder Known sensitivity quetiapine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Borderline personality disorder</keyword>
</DOC>